Gossamer Bio Announces Data Presentations at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting 2019 - Gossamer Bio (NASDAQ:GOSS)

Gossamer Bio, Inc. GOSS, a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB001, the Company's oral DP2 antagonist for the treatment of asthma and allergic disease, have been accepted for presentation at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting 2019 being held November 7- 11 in Houston, Texas.

Details for the ACAAI presentations are as follows:


Session Title:	E-posters – Meet the Authors: Session 1
Abstract Number:	P210
Abstract Title:	Indicators of Asthma Exacerbation Before Initiation of Biologic Therapy: A Real-world Experience
Presenter Name:	Hector Ortega, MD, ScD
Presentation Date/Time:	Friday, November 8; 5:30 – 5:45 p.m. CT
Location:	George R. Brown Convention Center, Halls A3 & B3 (Level 3), Monitor 8

Session Title:	E-posters – Meet the Authors: Session 2
Abstract Number:	P213
Abstract Title:	Phase 2 study results of DP2-antagonist GB001 on asthma worsening and other asthma control markers
Presenter Name:	Hector Ortega, MD, ScD
Presentation Date/Time:	Saturday, November 9; 11:45 a.m. – 12:00 p.m. CT
Location:	George R. Brown Convention Center, Halls A3 & B3 (Level 3), Monitor 8

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191108005080/en/

Market News and Data brought to you by Benzinga APIs